Libri di Reiner Bartl
Biografia e opere di Reiner Bartl
Osteoporosis
Bertha Frisch , Reiner Bartl
editore: Springer-Verlag Berlin and Heidelberg GmbH & Co. K
pagine: 331
Osteoporosis is a global threat because it can impact every human being as they age. In this new edition, the authors point out the enormous scale of the problem in terms of human suffering, morbidity and mortality on the one hand, and the astronomical national costs on the other. Written in an easy-to-read style, this book updates physicians on the current knowledge about bone structure, physiology and pathology, with an emphasis on the diagnosis, therapy and prevention of osteoporosis. Its purpose is to educate members of the medical profession about this widespread and potentially disabling disease, while providing information on related current evidence-based medicine. The book covers everything from basic physiology to osteoporosis diagnosis, including utility of specialized tests and current treatment recommendations, and will provide the primary care physician with sound medical knowledge in the prevention and management of osteoporosis. It is up-beat and optimistic, with a touch of humor; it is scientifically based but provides easy-to-follow guidelines for lifelong maintenance of skeletal structure and function.
Osteoporosis is preventable if doctors want it to be, and every doctor can contribute. Bone is every doctor's and every body's business.
A Pocket Guide to Bisphosphonates in Clinical Practice
Prevention and Therapy of Bone Disorders
Bertha Frisch , Reiner Bartl
editore: Blackwell Science Ltd
pagine: 150
The potential capacity of the biphosphonates to intervene in osseous remodeling was recognized more than 30 years ago. The biphosphonates inhibit osteoclastic activity. In spite of advances in early detection, surgey, chemo-and radiotherapy, metastatic bone disease is still a major and in many cases intractable clinical problem. The biphosphonates are now the most effective agents in the management of bone metastases - as shown by trials in patients with breast and prostate cancer, and in multiple myeloma. Bone pain, new ostelytic events and pathologic fractures are decreased and complications associated with these events are avoided. Existing osteolytic lesions may even be reversed. New fields of indications of biphosphonates are shown to be in the adjuvant therapy of breast cancer and in stage 1 multiple myeloma to prevent skeletal destruction and also to inhibit tumor growth. Over the past few years the biphosphonates have proved their value also in many other conditions such as Paget's disease of bone, osseous disorders with an osteoclastic component leading to osteopenia/osteoporosis, in congenial, endocrine and metabolic disorders.
Perhaps, for the future and for the next millennium the most widespread and extensive use to these anti-osteoclastic component leading to osteopenia/osteoporosis, in congenial, endocrine and metabolic disorders. Perhaps, for the future and for the next millennium the most widespread and extensive use to these anti-osteoclastic agents will be in these disorders, and particularly in so-called primary osteoporosis which evenually effects anyone who lives long enough, causing widespread morbidity with drastic economic consequences both individually and nationally. The authors' aim is to provide an office and desk companion - comprehensive, concise, practical for easy reference - an up-to-date guide for prevention and therapy of skeletal complications whenever and wherever they occur in general and specialized medical practice.
